Trial Profile
An Open Label International Multi-Center Phase 2 Activity And Safety Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Progressing Or Recurring After One Prior Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 17 Dec 2009 Patient numbers amended from 93 to 78 as reported by ClinicalTrials.gov.
- 10 Sep 2008 Actual patient number (93) added as reported by ClinicalTrials.gov.
- 10 Sep 2008 Actual end date (May 2008) added as reported by ClinicalTrials.gov.